According to the Zhitong Finance App, Yiming Angko-B (01541.HK) announced that the phase II clinical trial of IMM2510 (pervirafupe α) combined with IMM27M (tezesubizumab) for first-line treatment of patients with advanced hepatocellular carcinoma (“HCC”) successfully completed the first patient administration. The study aimed to evaluate the initial efficacy and safety of IMM2510 combined with IMM27M in this patient group.

According to the Zhitong Finance App, Yiming Angko-B (01541.HK) announced that the phase II clinical trial of IMM2510 (pervirafupe α) combined with IMM27M (tezesubizumab) for first-line treatment of patients with advanced hepatocellular carcinoma (“HCC”) successfully completed the first patient administration. The study aimed to evaluate the initial efficacy and safety of IMM2510 combined with IMM27M in this patient group.